Back

Candel Therapeutics publishes Phase 2a data showing prolonged survival in advanced NSCLC

Verifying
  • Candel Therapeutics announced publication of Phase 2a trial data for aglatimagene besadenovec plus valacyclovir.
  • Stage III/IV NSCLC patients had unresectable disease and inadequate responses to ICI therapy.
  • The data demonstrated prolonged survival after systemic immune reactivation.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.